Total Payments
$1.8M
2024 Payments
$145,678
Companies
50
Transactions
1,165
Medicare Patients
96
Medicare Billing
$6,046
Payment Breakdown by Category
Other$1.2M (66.3%)
Travel$302,827 (16.5%)
Consulting$290,493 (15.8%)
Food & Beverage$23,904 (1.3%)
Education$364.21 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 345 | 66.2% |
| Travel and Lodging | $302,827 | 371 | 16.5% |
| Consulting Fee | $290,493 | 57 | 15.8% |
| Food and Beverage | $23,904 | 377 | 1.3% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $2,500 | 1 | 0.1% |
| Education | $364.21 | 13 | 0.0% |
| Honoraria | $62.80 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $438,056 | 219 | $0 (2024) |
| Lilly USA, LLC | $270,356 | 156 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $265,165 | 193 | $0 (2024) |
| Merck Sharp & Dohme LLC | $202,294 | 163 | $0 (2023) |
| Boehringer Ingelheim South Africa (Pty) Ltd | $105,321 | 27 | $0 (2020) |
| Takeda Pharmaceuticals International, Inc. | $96,735 | 24 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $62,857 | 71 | $0 (2024) |
| Boehringer Ingelheim MENA (Scientific Office) FZ-LLC | $57,112 | 10 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $53,707 | 19 | $0 (2020) |
| Boehringer Ingelheim International GmbH | $53,704 | 12 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $145,678 | 102 | Novo Nordisk Inc ($82,072) |
| 2023 | $169,602 | 152 | Merck Sharp & Dohme LLC ($76,056) |
| 2022 | $209,676 | 162 | Novo Nordisk Inc ($101,469) |
| 2021 | $248,693 | 172 | Lilly USA, LLC ($109,900) |
| 2020 | $148,203 | 111 | Lilly USA, LLC ($51,100) |
| 2019 | $227,296 | 151 | Boehringer Ingelheim Pharmaceuticals, Inc. ($49,730) |
| 2018 | $273,886 | 143 | Novo Nordisk Inc ($81,046) |
| 2017 | $411,894 | 172 | Boehringer Ingelheim South Africa (Pty) Ltd ($64,489) |
All Payment Transactions
1,165 individual payment records from CMS Open Payments — Page 1 of 47
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,040.00 | General |
| Category: Diabetes | ||||||
| 12/13/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,135.00 | General |
| Category: Diabetes | ||||||
| 12/04/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,520.00 | General |
| Category: Diabetes | ||||||
| 11/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,700.00 | General |
| Category: DIABETES | ||||||
| 11/11/2024 | BIOTRONIK INC. | Orsiro Mission (Device) | Food and Beverage | In-kind items and services | $24.81 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/07/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,493.75 | General |
| 11/07/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $1,002.40 | General |
| 11/07/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $838.68 | General |
| 11/07/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $163.88 | General |
| 11/07/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $66.82 | General |
| 11/03/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $124.99 | General |
| 10/22/2024 | BIOTRONIK INC. | Orsiro Mission (Device) | Food and Beverage | In-kind items and services | $35.08 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Travel and Lodging | In-kind items and services | $1,530.11 | General |
| Category: DIABETES | ||||||
| 10/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Travel and Lodging | In-kind items and services | $168.27 | General |
| Category: DIABETES | ||||||
| 10/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,175.00 | General |
| Category: DIABETES | ||||||
| 10/09/2024 | Dr.Reddy's Laboratories,Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| 09/30/2024 | Abbott Laboratories | GALLANT (Device) | Food and Beverage | In-kind items and services | $166.58 | General |
| Category: Cardiac Rhythm Management | ||||||
| 09/24/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,331.25 | General |
| 09/24/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $1,209.98 | General |
| 09/24/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $503.90 | General |
| 09/24/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $130.10 | General |
| 09/24/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $117.53 | General |
| 09/17/2024 | BIOTRONIK INC. | Passeo-18 (Device), Pulsar-18 T3 | Food and Beverage | In-kind items and services | $20.67 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: DIABETES | ||||||
| 09/11/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,943.75 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 13 | 13 | $468.00 | $125.97 |
| 2022 | 1 | 12 | 12 | $2,916 | $921.78 |
| 2021 | 2 | 36 | 37 | $6,337 | $2,012 |
| 2020 | 2 | 35 | 45 | $9,168 | $2,986 |
Total Patients
96
Total Services
107
Medicare Billing
$6,046
Procedure Codes
6
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 13 | 13 | $468.00 | $125.97 | 26.9% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 12 | 12 | $2,916 | $921.78 | 31.6% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 23 | 24 | $5,867 | $1,885 | 32.1% |
| 99152 | Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 15 minutes | Facility | 2021 | 13 | 13 | $470.00 | $127.53 | 27.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 19 | 29 | $5,168 | $1,683 | 32.6% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 16 | 16 | $4,000 | $1,302 | 32.6% |
About Dr. Robert Chilton, DO
Dr. Robert Chilton, DO is a Cardiovascular Disease healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538276514.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Chilton, DO has received a total of $1.8M in payments from pharmaceutical and medical device companies, with $145,678 received in 2024. These payments were reported across 1,165 transactions from 50 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.2M).
As a Medicare-enrolled provider, Chilton has provided services to 96 Medicare beneficiaries, totaling 107 services with total Medicare billing of $6,046. Data is available for 4 years (2020–2023), covering 6 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Interventional Cardiology
- Location San Antonio, TX
- Active Since 08/24/2006
- Last Updated 03/05/2019
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1538276514
Products in Payments
- JARDIANCE (Drug) $652,214
- VERQUVO (Drug) $151,590
- Ozempic (Drug) $139,985
- Victoza (Drug) $106,130
- TRULICITY (Drug) $101,500
- FARXIGA (Drug) $47,187
- Nesina (Drug) $39,729
- SOLIQUA (Drug) $30,227
- Edarbi (Drug) $23,120
- Wegovy (Drug) $22,273
- TRADJENTA (Drug) $20,683
- NO PRODUCT DISCUSSED (Drug) $16,430
- Rybelsus (Drug) $12,888
- PRALUENT (Biological) $12,416
- EMPAGLIFLOZIN (Drug) $11,546
- PRADAXA (Drug) $10,745
- Repatha (Biological) $10,153
- Vascepa (Drug) $8,319
- GLYXAMBI (Drug) $8,235
- RYBELSUS (Drug) $6,375
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in San Antonio
Dr. Chandrasekhar Kunavarapu, M.d, M.D
Cardiovascular Disease — Payments: $456,612
Cardiovascular Disease $456,612
Eric Stocker, Md, MD
Cardiovascular Disease — Payments: $376,204
Cardiovascular Disease $376,204
Mark Colligan, Md, MD
Cardiovascular Disease — Payments: $198,267
Cardiovascular Disease $198,267
Wassim Choucair, M.d, M.D
Cardiovascular Disease — Payments: $135,616
Cardiovascular Disease $135,616
Dr. Jamil Malik, Md, MD
Cardiovascular Disease — Payments: $105,345
Cardiovascular Disease $105,345
Chad Christopherson, Md, MD
Cardiovascular Disease — Payments: $104,738
Cardiovascular Disease $104,738